Patents by Inventor Hiroyuki Aburatani
Hiroyuki Aburatani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210380715Abstract: It is intended to disclose an antibody which binds to DLL3 protein. Preferably, the antibody of the present invention recognizes a region from amino acids 216 to 492 in human DLL3 having the amino acid sequence as set forth in SEQ ID NO: 1. The present invention also provides a pharmaceutical composition, for example, an anticancer agent, comprising the antibody of the present invention as an active ingredient. The present invention further discloses a method for diagnosing cancer using the antibody of the present invention and a diagnostic drug for cancer comprising the antibody of the present invention.Type: ApplicationFiled: August 19, 2021Publication date: December 9, 2021Applicants: CHUGAI SEIYAKU KABUSHIKI KAISHA, THE UNIVERSITY OF TOKYOInventors: Kenji YOSHIDA, Hiroyuki Aburatani, Shumpei Ishikawa
-
Patent number: 11111311Abstract: It is intended to disclose an antibody which binds to DLL3 protein. Preferably, the antibody of the present invention recognizes a region from amino acids 216 to 492 in human DLL3 having the amino acid sequence as set forth in SEQ ID NO: 1. The present invention also provides a pharmaceutical composition, for example, an anticancer agent, comprising the antibody of the present invention as an active ingredient. The present invention further discloses a method for diagnosing cancer using the antibody of the present invention and a diagnostic drug for cancer comprising the antibody of the present invention.Type: GrantFiled: September 4, 2015Date of Patent: September 7, 2021Assignees: CHUGAI SEIYAKU KABUSHIKI KAISHA, THE UNIVERSITY OF TOKYOInventors: Kenji Yoshida, Hiroyuki Aburatani, Shumpei Ishikawa
-
Patent number: 10696743Abstract: Methods that involve detection of a DSG3 protein for diagnosing cancer are disclosed. In lung cancer, the expression of DSG3 was found to be enhanced at very high frequency at the gene level and protein level. Methods of the present invention can be carried out using an antibody that recognizes a DSG3 protein. Pharmaceutical compositions, cell growth inhibitors, and anticancer agents containing a DSG3-binding antibody as an active ingredient are also disclosed. Methods of inducing cell damage in DSG3-expressing cells and methods of suppressing proliferation of DSG3-expressing cells by contacting the DSG3-expressing cells with DSG3-binding antibodies are also disclosed.Type: GrantFiled: February 10, 2017Date of Patent: June 30, 2020Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hiroyuki Aburatani, Shunpei Ishikawa, Hirotaka Ito, Kiyotaka Nakano, Shigeto Kawai
-
Publication number: 20200181248Abstract: Disclosed is an antibody against a secreted form of GPC3 capable of detecting a secreted form of glypican 3 (GPC3) in a test sample. It is possible to determine whether a subject suffers from cancer, in particular hepatoma. Also disclosed is an antibody against GPC as well as a cell disrupting agent and an anti-cancer agent comprising the same, which can disrupt cells, in particular cancer cells.Type: ApplicationFiled: December 2, 2019Publication date: June 11, 2020Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Hiroyuki ABURATANI, Yutaka MIDORIKAWA, Kiyotaka NAKANO, Iwao OHIZUMI, Yukio ITO, Susumu TOKITA
-
Publication number: 20200157231Abstract: With dedicated research, the present inventors discovered that not only the LGR7 gene but also the LGR7 protein are highly expressed in clear cell adenocarcinoma cells of ovarian cancer. Furthermore, the present inventors found that anti-LGR7 antibodies have antibody-dependent cell-mediated cytotoxicity (ADCC) activity and complement-dependent cytotoxicity (CDC) activity against LGR7-expressing cells. From the above findings, the present inventors discovered that the anti-LGR7 antibodies are useful for diagnosis, prevention, and treatment of primary and metastatic ovarian clear cell adenocarcinoma.Type: ApplicationFiled: February 5, 2020Publication date: May 21, 2020Inventors: Hiroyuki ABURATANI, Yuriko UEHARA, Shinichi FUNAHASHI
-
Publication number: 20200056177Abstract: The present invention provides a novel long non-coding RNA (lncRNA), which is induced by ?-catenin and highly expressed in cancer, a nucleic acid that suppresses expression of the lncRNA, a means for promoting or suppressing cell growth by using the lncRNA or the nucleic acid, and the like.Type: ApplicationFiled: June 14, 2019Publication date: February 20, 2020Applicant: THE UNIVERSITY OF TOKYOInventors: Hiroyuki ABURATANI, Aya NONAKA, Tatsuya MIYAZAWA, Tetsuo YOSHIDA
-
Patent number: 10563265Abstract: Disclosed are a novel method of detecting cancer, a method of screening inhibitors and anticancer agents that target cancer-related molecules, RHOA polypeptide having mutation and a polynucleotide encoding the polypeptide as a therapeutic agent for cancer, and a method of detecting cancer using the polypeptide or polynucleotide. Also disclosed are a vector and a host cell comprising the polynucleotide, a method of screening therapeutic agents for cancer comprising the polypeptide and/or the polynucleotide, and a therapeutic agent for cancer comprising siRNA having a silencing effect on RHOA mutant.Type: GrantFiled: September 4, 2014Date of Patent: February 18, 2020Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hiroyuki Aburatani, Shumpei Ishikawa, Miwako Kakiuchi, Takashi Nishizawa
-
Patent number: 10186332Abstract: A determination device for enabling a computer to carry out a process including the steps of: obtaining an analysis result on methylation status of a CpG site located in a promoter region of at least one gene selected from HOXB4 (Homeobox B4) and ZSCAN31 (zinc finger and SCAN domain containing 31) in a DNA sample derived from a subject; and outputting a determination result as information on lung cancer in the subject based on the resulting analysis result is provided. A computer readable medium and a marker for obtaining information on lung cancer are also provided.Type: GrantFiled: July 9, 2015Date of Patent: January 22, 2019Assignees: SYSMEX CORPORATION, THE UNIVERSITY OF TOKYOInventors: Kaya Tai, Genta Nagae, Hiroyuki Aburatani
-
Publication number: 20180155438Abstract: Disclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a cell growth inhibitor, and an anticancer agent containing the antibody as an active ingredient, and a method for treating cancer, a method for predicting the efficacy of cancer treatment, and a method for determining the presence of cancer in a test subject using the antibody.Type: ApplicationFiled: January 24, 2018Publication date: June 7, 2018Applicants: THE UNIVERSITY OF TOKYO, CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Hiroyuki ABURATANI, Shumpei ISHIKAWA, Shigeto KAWAI
-
Patent number: 9920129Abstract: Disclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a cell growth inhibitor, and an anticancer agent containing the antibody as an active ingredient, and a method for treating cancer, a method for predicting the efficacy of cancer treatment, and a method for determining the presence of cancer in a test subject using the antibody.Type: GrantFiled: April 29, 2016Date of Patent: March 20, 2018Assignees: THE UNIVERSITY OF TOKYO, CHUGAI SEIY AKU KABUSHIKI KAISHAInventors: Hiroyuki Aburatani, Shumpei Ishikawa, Shigeto Kawai
-
Publication number: 20170356051Abstract: The present invention relates to a method for predicting responsiveness to cancer drug therapy for colorectal cancer. More particularly, the present invention relates to a method for predicting the responsiveness of a colorectal cancer patient to cancer drug therapy, the method comprising analyzing the level of DNA methylation in a specimen comprising a colorectal cancer tissue, colorectal cancer cells, or colorectal cancer cell-derived DNA of a subject, and then determining the responsiveness of the subject to cancer drug therapy based on the level of DNA methylation.Type: ApplicationFiled: October 16, 2015Publication date: December 14, 2017Inventors: Chikashi ISHIOKA, Shin TAKAHASHI, Kouta OUCHI, Hideki SHIMODAIRA, Hiroyuki ABURATANI
-
Publication number: 20170233462Abstract: Disclosed is an antibody against a secreted form of GPC3 capable of detecting a secreted form of glypican 3 (GPC3) in a test sample. It is possible to determine whether a subject suffers from cancer, in particular hepatoma. Also disclosed is an antibody against GPC as well as a cell disrupting agent and an anti-cancer agent comprising the same, which can disrupt cells, in particular cancer cells.Type: ApplicationFiled: October 7, 2016Publication date: August 17, 2017Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Hiroyuki ABURATANI, Yutaka Midorikawa, Kiyotaka Nakano, Iwao Ohizumi, Yukio Ito, Susumu Tokita
-
Publication number: 20170152314Abstract: Methods that involve detection of a DSG3 protein for diagnosing cancer are disclosed. In lung cancer, the expression of DSG3 was found to be enhanced at very high frequency at the gene level and protein level. Methods of the present invention can be carried out using an antibody that recognizes a DSG3 protein. Pharmaceutical compositions, cell growth inhibitors, and anticancer agents containing a DSG3-binding antibody as an active ingredient are also disclosed. Methods of inducing cell damage in DSG3-expressing cells and methods of suppressing proliferation of DSG3-expressing cells by contacting the DSG3-expressing cells with DSG3-binding antibodies are also disclosed.Type: ApplicationFiled: February 10, 2017Publication date: June 1, 2017Inventors: Hiroyuki ABURATANI, Shunpei Ishikawa, Hirotaka Ito, Kiyotaka Nakano, Shigeto Kawai
-
Patent number: 9644029Abstract: A method for diagnosing cancer comprising detecting ROBO1 protein is disclosed. In addition, a method for treating a disease caused by abnormal cell growth comprising administrating an antibody that binds to ROBO1, as well as a pharmaceutical composition, a cell growth inhibitor and an anticancer agent comprising an antibody that binds to ROBO1 as an active ingredient are disclosed. Further, a method for inducing cell damages in a ROBO1 expressing cell and a method for inhibiting the growth of a ROBO1 expressing cell by bringing a ROBO1 expressing cell into contact with an antibody that binds to ROBO1, are disclosed. Furthermore, a method for monitoring progression of hepatitis by detecting ROBO1 protein is disclosed.Type: GrantFiled: December 11, 2014Date of Patent: May 9, 2017Assignees: Perseus Proteomics Inc., Chugai Seiyaku Kabushiki KaishaInventors: Hiroyuki Aburatani, Yoshitaka Hippo, Akira Watanabe, Masashi Fukayama, Yukio Ito, Masahiro Arai, Hirotaka Ito, Toshihiko Ohtomo, Shin-ichi Funahashi, Yasuko Kinoshita
-
Patent number: 9513292Abstract: Provided is a method for diagnosing cancer by detecting a novel cancer marker. Cancer can be diagnosed by detecting soluble glypican 3 in a test sample.Type: GrantFiled: December 22, 2014Date of Patent: December 6, 2016Assignee: Perseus Proteomics Inc.Inventors: Hiroyuki Aburatani, Yutaka Midorikawa, Kiyotaka Nakano, Iwao Ohizumi, Yukio Ito, Susumu Tokita
-
Publication number: 20160311920Abstract: Disclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a cell growth inhibitor, and an anticancer agent containing the antibody as an active ingredient, and a method for treating cancer, a method for predicting the efficacy of cancer treatment, and a method for determining the presence of cancer in a test subject using the antibody.Type: ApplicationFiled: April 29, 2016Publication date: October 27, 2016Applicants: THE UNIVERSITY OF TOKYO, CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Hiroyuki ABURATANI, Shumpei ISHIKAWA, Shigeto KAWAI
-
Patent number: 9434775Abstract: Disclosed are a protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a fragment thereof, an antibody recognizing the protein or antigen-binding fragment thereof, and a polynucleotide having a sequence comprising at least 12 consecutive nucleotides of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a nucleotide sequence complementary thereto. The gene and the protein of the invention is useful for diagnosing and treating cancer.Type: GrantFiled: April 1, 2009Date of Patent: September 6, 2016Assignees: Perseus Proteomics Inc., Chugai Seiyaku Kabushiki KaishaInventors: Hiroyuki Aburatani, Yoshitaka Hippo, Hirokazu Taniguchi, Yong xin Chen, Shumpei Ishikawa, Shin-ichi Fukumoto, Takahiro Shimamura, Naoka Kamimura, Ying qiu Guo, Shogo Yamamoto, Yukio Ito, Hirotaka Ito, Toshihiko Ohtomo
-
Publication number: 20160244530Abstract: It is intended to disclose an antibody which binds to DLL3 protein. Preferably, the antibody of the present invention recognizes a region from amino acids 216 to 492 in human DLL3 having the amino acid sequence as set forth in SEQ ID NO: 1. The present invention also provides a pharmaceutical composition, for example, an anticancer agent, comprising the antibody of the present invention as an active ingredient. The present invention further discloses a method for diagnosing cancer using the antibody of the present invention and a diagnostic drug for cancer comprising the antibody of the present invention.Type: ApplicationFiled: September 4, 2015Publication date: August 25, 2016Applicants: CHUGAI SEIYAKU KABUSHIKI KAISHA, THE UNIVERSITY OF TOKYOInventors: Kenji YOSHIDA, Hiroyuki ABURATANI, Shumpei ISHIKAWA
-
Publication number: 20160208335Abstract: Disclosed are a novel method of detecting cancer, a method of screening inhibitors and anticancer agents that target cancer-related molecules, RHOA polypeptide having mutation and a polynucleotide encoding the polypeptide as a therapeutic agent for cancer, and a method of detecting cancer using the polypeptide or polynucleotide. Also disclosed are a vector and a host cell comprising the polynucleotide, a method of screening therapeutic agents for cancer comprising the polypeptide and/or the polynucleotide, and a therapeutic agent for cancer comprising siRNA having a silencing effect on RHOA mutant.Type: ApplicationFiled: September 4, 2014Publication date: July 21, 2016Applicants: The University of Tokyo, Chugai Seiyaku Kabushiki KaishaInventors: Hiroyuki ABURATANI, Shumpei ISHIKAWA, Miwako KAKIUCHI, Takashi NISHIZAWA
-
Patent number: 9376475Abstract: Disclosed are a protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a fragment thereof, an antibody recognizing the protein or antigen-binding fragment thereof, and a polynucleotide having a sequence comprising at least 12 consecutive nucleotides of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a nucleotide sequence complementary thereto. The gene and the protein of the invention is useful for diagnosing and treating cancer.Type: GrantFiled: August 31, 2010Date of Patent: June 28, 2016Assignees: Perseus Proteomics Inc., Chugai Seiyak Kabushiki KaishaInventors: Hiroyuki Aburatani, Yoshitaka Hippo, Hirokazu Taniguchi, Yong xin Chen, Shumpei Ishikawa, Shin-ichi Fukumoto, Takahiro Shimamura, Naoko Kamimura, Ying qiu Guo, Shogo Yamamoto, Yukio Ito, Hirotaka Ito, Toshihiko Ohtomo